206. Fragile X syndrome
98 clinical trials,   73 drugs   (DrugBank: 27 drugs),   46 drug target genes,   57 drug target pathways
Searched query = "Fragile X syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT03624556 (ClinicalTrials.gov) | January 29, 2018 | 6/6/2018 | Pediatric Exploratory Research Study of EGCG Use and Safety (PERSEUS) | Pediatric Exploratory Research Study of EGCG Use and Safety (PERSEUS) | Down Syndrome;Fragile X Syndrome | Dietary Supplement: EGCG FontUp;Other: Placebo FontUp | Parc de Salut Mar | Hospital Infantil Universitario Niño Jesús, Madrid, Spain;Instituto Hispalense de Pediatría, Sevilla, Spain;Hospital Universitario Marqués de Valdecilla;Institut Jerome Lejeune | Active, not recruiting | 6 Years | 12 Years | All | 70 | N/A | Spain |
2 | NCT01855971 (ClinicalTrials.gov) | June 11, 2013 | 9/5/2013 | Using Epigallocatechin Gallate (EGCG) and Cognitive Training to Modulate Cognitive Performance in Patients With Fragile X Syndrome (TESFX) | Estrogen Receptors Beta (ER-B) as Therapeutic Targets for the Improvement of Cognitive Performance in Fragile-X (TESXF) | Fragile X Syndrome | Dietary Supplement: EGCG;Dietary Supplement: Placebo;Other: Cognitive training | Parc de Salut Mar | NULL | Completed | 18 Years | 60 Years | All | 44 | Phase 2 | Spain |